A04AA01 - Ondansetron |
Probably not porphyrinogenic |
PNP |
Rationale
Metabolised by CYP3A4 but no clinical data pointing to CYP-induction. Two references stating non-porphyrinogenicity.
Chemical description
Selective 5-HT-antagonist used as antiemetic for postoperative nausea and nausea under chemotherapy, 4-32 mg/d given perorally or intravenously. Hydroxylated and conjugated to glucuronic acid and sulfate via CYP 3A4. No instances of clinically significant CYP-induction observed.
IPNet drug reports
Uneventful use reported in 12 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PubMed ID |
|---|---|---|
| 1. | Ondansetron in a patient with porphyria.
De Wet M, Jooste R, et al. S Afr Med J. 1992 Dec; 82(6):480.
|
1465703 |
| 2. | Drugs in the acute porphyrias--toxicogenetic diseases.
Moore MR, Hift RJ. Cell Mol Biol (Noisy-le-grand). 1997 Feb; 43(1):89-94.
|
9074793 |
| Porphyria Drug Lists | ||
| 3. | French List
Centre Français des Porphyries
|
|
| 4. | South African List
Porphyria South Africa No longer maintained
|
|
Tradenames